This article is more than 5 years old. Information may no longer be current.

Akorn to re-launch erythromycin ophthalmic ointment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LAKE FOREST, Ill. — The U.S. Food and Drug Administration has approved Akorn's supplemental abbreviated new drug application to once again distribute 3.5-g tubes of erythromycin ophthalmic ointment, according to a press release from the company.

"We identified an opportunity to re-launch erythromycin as ongoing market shortages have made this an attractive product which is complementary to the other ophthalmic ointments Akorn currently sells," Raj Rai, interim CEO of Akorn, said in the release.

Akorn plans to begin distributing erythromycin ophthalmic ointment immediately.

Follow OSNSuperSite.com on Twitter.